Literature DB >> 16530456

Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells.

Ute Panzenboeck1, Ingrid Kratzer, Andrea Sovic, Andrea Wintersperger, Eva Bernhart, Astrid Hammer, Ernst Malle, Wolfgang Sattler.   

Abstract

The blood-brain barrier contributes to maintain brain cholesterol metabolism and protects this uniquely balanced system from exchange with plasma lipoprotein cholesterol. Brain capillary endothelial cells, representing a physiological barrier to the central nervous system, express apolipoprotein A-I (apoA-I, the major high-density lipoprotein (HDL)-associated apolipoprotein), ATP-binding cassette transporter A1 (ABCA1), and scavenger receptor, class B, type I (SR-BI), proteins that promote cellular cholesterol mobilization. Liver X receptors (LXRs) and peroxisome-proliferator activated receptors (PPARs) are regulators of cholesterol transport, and activation of LXRs and PPARs has potential therapeutic implications for lipid-related neurodegenerative diseases. To clarify the functional impact of LXR/PPAR activation, sterol transport along the: (i) ABCA1/apoA-I and (ii) SR-BI/HDL pathway was investigated in primary, polarized brain capillary endothelial cells, an in vitro model of the blood-brain barrier. Activation of LXR (24(S)OH-cholesterol, TO901317), PPARalpha (bezafibrate, fenofibrate), and PPARgamma (troglitazone, pioglitazone) modulated expression of apoA-I, ABCA1, and SR-BI on mRNA and/or protein levels without compromising transendothelial electrical resistance or tight junction protein expression. LXR-agonists and troglitazone enhanced basolateral-to-apical cholesterol mobilization in the absence of exogenous sterol acceptors. Along with the induction of cell surface-located ABCA1, several agonists enhanced cholesterol mobilization in the presence of exogenous apoA-I, while efflux of 24(S)OH-cholesterol (the major brain cholesterol metabolite) in the presence of exogenous HDL remained unaffected. Summarizing, in cerebrovascular endothelial cells apoA-I, ABCA1, and SR-BI represent drug targets for LXR and PPAR-agonists to interfere with cholesterol homeostasis at the periphery of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530456     DOI: 10.1016/j.biocel.2006.01.013

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  21 in total

1.  Blood-brain barrier pathophysiology in traumatic brain injury.

Authors:  Adam Chodobski; Brian J Zink; Joanna Szmydynger-Chodobska
Journal:  Transl Stroke Res       Date:  2011-12       Impact factor: 6.829

Review 2.  Cytokine signaling modulates blood-brain barrier function.

Authors:  Weihong Pan; Kirsten P Stone; Hung Hsuchou; Vamshi K Manda; Yan Zhang; Abba J Kastin
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

3.  Afamin is synthesized by cerebrovascular endothelial cells and mediates alpha-tocopherol transport across an in vitro model of the blood-brain barrier.

Authors:  Ingrid Kratzer; Eva Bernhart; Andrea Wintersperger; Astrid Hammer; Sabine Waltl; Ernst Malle; Günther Sperk; Georg Wietzorrek; Hans Dieplinger; Wolfgang Sattler
Journal:  J Neurochem       Date:  2008-11-27       Impact factor: 5.372

Review 4.  The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration.

Authors:  Radosveta Koldamova; Nicholas F Fitz; Iliya Lefterov
Journal:  Biochim Biophys Acta       Date:  2010-02-24

Review 5.  Cholesterol metabolism in Huntington disease.

Authors:  Joanna M Karasinska; Michael R Hayden
Journal:  Nat Rev Neurol       Date:  2011-09-06       Impact factor: 42.937

6.  Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function.

Authors:  Joanna M Karasinska; Franz Rinninger; Dieter Lütjohann; Piers Ruddle; Sonia Franciosi; Janine K Kruit; Roshni R Singaraja; Veronica Hirsch-Reinshagen; Jianjia Fan; Liam R Brunham; Nagat Bissada; Rajasekhar Ramakrishnan; Cheryl L Wellington; John S Parks; Michael R Hayden
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

7.  Phospholipid transfer protein is expressed in cerebrovascular endothelial cells and involved in high density lipoprotein biogenesis and remodeling at the blood-brain barrier.

Authors:  Anil Paul Chirackal Manavalan; Alexandra Kober; Jari Metso; Ingrid Lang; Tatjana Becker; Karin Hasslitzer; Martina Zandl; Elham Fanaee-Danesh; Jyotsna Brijesh Pippal; Vinay Sachdev; Dagmar Kratky; Jasminka Stefulj; Matti Jauhiainen; Ute Panzenboeck
Journal:  J Biol Chem       Date:  2013-12-25       Impact factor: 5.157

8.  The neurorestorative benefit of GW3965 treatment of stroke in mice.

Authors:  Xu Cui; Michael Chopp; Alex Zacharek; Yisheng Cui; Cynthia Roberts; Jieli Chen
Journal:  Stroke       Date:  2012-11-29       Impact factor: 7.914

9.  Interleukin-6 inhibition of peroxisome proliferator-activated receptor alpha expression is mediated by JAK2- and PI3K-induced STAT1/3 in HepG2 hepatocyte cells.

Authors:  Guat-Siew Chew; Stephen Myers; Alexander Chong Shu-Chien; Tengku Sifzizul Tengku Muhammad
Journal:  Mol Cell Biochem       Date:  2013-11-16       Impact factor: 3.396

10.  Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier.

Authors:  Ingrid Kratzer; Karin Wernig; Ute Panzenboeck; Eva Bernhart; Helga Reicher; Robert Wronski; Manfred Windisch; Astrid Hammer; Ernst Malle; Andreas Zimmer; Wolfgang Sattler
Journal:  J Control Release       Date:  2006-11-28       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.